New Frontiers in Druggability

Journal of Medicinal Chemistry

Volumn 58, Issue 23, 2015, Pages 9063-9088

  Kozakov, Dima ^a   Hall, David R ^b   Napoleon, Raeanne L ^c   Yueh, Christine ^d   Whitty, Adrian ^c   Vajda, Sandor ^c,d  

^a Stony Brook University   (United States)

^b Acpharis Inc   (United States)

^c Boston University   (United States)

^d Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROCYCLIC COMPOUND; LIGAND; PROTEIN;

ANALYTIC METHOD; BINDING AFFINITY; BIOPHYSICS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG ACTIVITY; DRUG TARGETING; DRUGGABILITY; HYDROGEN BOND; INFORMATION PROCESSING; MATHEMATICAL COMPUTING; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN BINDING; REVIEW; ANIMAL; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; COMPUTER-AIDED DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; MACROCYCLIC COMPOUNDS; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPS; PROTEINS;

EID: 84946216702     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00586     Document Type: Review

References (163)

1. Hopkins, A. L.; Groom, C. R. The druggable genome Nat. Rev. Drug Discovery 2002, 1, 727-30 10.1038/nrd892
2. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26 10.1016/S0169-409X(00)00129-0
3. Russ, A. P.; Lampel, S. The druggable genome: An update Drug Discovery Today 2005, 10, 1607-10 10.1016/S1359-6446(05)03666-4
4. Johns, M. A.; Russ, A.; Fu, H. A. Current drug targets and the druggable genome Chemical Genomics 2012, 320-32 10.1017/CBO9781139021500.029
5. Sheridan, R. P.; Maiorov, V. N.; Holloway, M. K.; Cornell, W. D.; Gao, Y. D. Drug-like density: A method of quantifying the bindability of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank J. Chem. Inf. Model. 2010, 50, 2029-40 10.1021/ci100312t
6. Hajduk, P. J.; Huth, J. R.; Tse, C. Predicting protein druggability Drug Discovery Today 2005, 10, 1675-82 10.1016/S1359-6446(05)03624-X
7. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-25 10.1021/jm049131r
8. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability Nat. Biotechnol. 2007, 25, 71-5 10.1038/nbt1273
9. Seco, J.; Luque, F. J.; Barril, X. Binding site detection and druggability index from first principles J. Med. Chem. 2009, 52, 2363-71 10.1021/jm801385d
10. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 2009, 49, 377-89 10.1021/ci800324m
11. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites J. Med. Chem. 2010, 53, 5858-67 10.1021/jm100574m
12. Krasowski, A.; Muthas, D.; Sarkar, A.; Schmitt, S.; Brenk, R. Drugpred: A structure-based approach to predict protein druggability developed using an extensive nonredundant data set J. Chem. Inf. Model. 2011, 51, 2829-42 10.1021/ci200266d
13. Fauman, E. B.; Rai, B. K.; Huang, E. S. Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics Curr. Opin. Chem. Biol. 2011, 15, 463-8 10.1016/j.cbpa.2011.05.020
14. Volkamer, A.; Kuhn, D.; Rippmann, F.; Rarey, M. Dogsitescorer: A web server for automatic binding site prediction, analysis and druggability assessment Bioinformatics 2012, 28, 2074-5 10.1093/bioinformatics/bts310
15. Nisius, B.; Sha, F.; Gohlke, H. Structure-based computational analysis of protein binding sites for function and druggability prediction J. Biotechnol. 2012, 159, 123-34 10.1016/j.jbiotec.2011.12.005
16. Perola, E.; Herman, L.; Weiss, J. Development of a rule-based method for the assessment of protein druggability J. Chem. Inf. Model. 2012, 52, 1027-38 10.1021/ci200613b
17. Volkamer, A.; Kuhn, D.; Grombacher, T.; Rippmann, F.; Rarey, M. Combining global and local measures for structure-based druggability predictions J. Chem. Inf. Model. 2012, 52, 360-72 10.1021/ci200454v
18. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery - an underexploited structural class Nat. Rev. Drug Discovery 2008, 7, 608-24 10.1038/nrd2590
19. Wessjohann, L. A.; Ruijter, E.; Garcia-Rivera, D.; Brandt, W. What can a chemist learn from nature's macrocycles? - A brief, conceptual view Mol. Diversity 2005, 9, 171-86 10.1007/s11030-005-1314-x
20. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: Applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 2011, 54, 1961-2004 10.1021/jm1012374
21. Mallinson, J.; Collins, I. Macrocycles in new drug discovery Future Med. Chem. 2012, 4, 1409-38 10.4155/fmc.12.93
22. Kalgutkar, A. S.; Dalvie, D. K. Drug discovery for a new generation of covalent drugs Expert Opin. Drug Discovery 2012, 7, 561-81 10.1517/17460441.2012.688744
23. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nat. Rev. Drug Discovery 2011, 10, 307-17 10.1038/nrd3410
24. Way, J. C. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs Curr. Opin. Chem. Biol. 2000, 4, 40-6 10.1016/S1367-5931(99)00049-6
25. Edwards, T. A.; Wilson, A. J. Helix-mediated protein - protein interactions as targets for intervention using foldamers Amino Acids 2011, 41, 743-54 10.1007/s00726-011-0880-8
26. Murray, J. K.; Gellman, S. H. Targeting protein-protein interactions: Lessons from p53/MDM2 Biopolymers 2007, 88, 657-86 10.1002/bip.20741
27. Raj, M.; Bullock, B. N.; Arora, P. S. Plucking the high hanging fruit: A systematic approach for targeting protein-protein interactions Bioorg. Med. Chem. 2013, 21, 4051-7 10.1016/j.bmc.2012.11.023
28. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix Science 2004, 305, 1466-70 10.1126/science.1099191
29. Brown, S. P.; Hajduk, P. J. Effects of conformational dynamics on predicted protein druggability ChemMedChem 2006, 1, 70-2 10.1002/cmdc.200500013
30. Clackson, T.; Wells, J. A. A hot spot of binding energy in a hormone-receptor interface Science 1995, 267, 383-6 10.1126/science.7529940
31. DeLano, W. L. Unraveling hot spots in binding interfaces: Progress and challenges Curr. Opin. Struct. Biol. 2002, 12, 14-20 10.1016/S0959-440X(02)00283-X
32. Keskin, O.; Ma, B. Y.; Nussinov, R. Hot regions in protein-protein interactions: The organization and contribution of structurally conserved hot spot residues J. Mol. Biol. 2005, 345, 1281-94 10.1016/j.jmb.2004.10.077
33. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces J. Mol. Biol. 1998, 280, 1-9 10.1006/jmbi.1998.1843
34. Kortemme, T.; Baker, D. A simple physical model for binding energy hot spots in protein-protein complexes Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 14116-21 10.1073/pnas.202485799
35. Mattos, C.; Ringe, D. Locating and characterizing binding sites on proteins Nat. Biotechnol. 1996, 14, 595-9 10.1038/nbt0596-595
36. Allen, K. N.; Bellamacina, C. R.; Ding, X. C.; Jeffery, C. J.; Mattos, C.; Petsko, G. A.; Ringe, D. An experimental approach to mapping the binding surfaces of crystalline proteins J. Phys. Chem. 1996, 100, 2605-11 10.1021/jp952516o
37. English, A. C.; Done, S. H.; Caves, L. S.; Groom, C. R.; Hubbard, R. E. Locating interaction sites on proteins: The crystal structure of thermolysin soaked in 2% to 100% isopropanol Proteins: Struct., Funct., Genet. 1999, 37, 628-40 10.1002/(SICI)1097-0134(19991201)37:4<628::AID-PROT13>3.3.CO;2-7
38. English, A. C.; Groom, C. R.; Hubbard, R. E. Experimental and computational mapping of the binding surface of a crystalline protein Protein Eng., Des. Sel. 2001, 14, 47-59 10.1093/protein/14.1.47
39. Dechene, M.; Wink, G.; Smith, M.; Swartz, P.; Mattos, C. Multiple solvent crystal structures of ribonuclease A: An assessment of the method Proteins: Struct., Funct., Genet. 2009, 76, 861-81 10.1002/prot.22393
40. Buhrman, G.; O'Connor, C.; Zerbe, B.; Kearney, B. M.; Napoleon, R.; Kovrigina, E. A.; Vajda, S.; Kozakov, D.; Kovrigin, E. L.; Mattos, C. Analysis of binding site hot spots on the surface of Ras GTPase J. Mol. Biol. 2011, 413, 773-89 10.1016/j.jmb.2011.09.011
41. Edfeldt, F. N. B.; Folmer, R. H. A.; Breeze, A. L. Fragment screening to predict druggability (ligandability) and lead discovery success Drug Discovery Today 2011, 16, 284-287 10.1016/j.drudis.2011.02.002
42. Barelier, S.; Krimm, I. Ligand specificity, privileged substructures and protein druggability from fragment-based screening Curr. Opin. Chem. Biol. 2011, 15, 469-74 10.1016/j.cbpa.2011.02.020
43. Dennis, S.; Kortvelyesi, T.; Vajda, S. Computational mapping identifies the binding sites of organic solvents on proteins Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 4290-5 10.1073/pnas.062398499
44. Landon, M. R.; Lancia, D. R., Jr.; Yu, J.; Thiel, S. C.; Vajda, S. Identification of hot spots within druggable binding regions by computational solvent mapping of proteins J. Med. Chem. 2007, 50, 1231-40 10.1021/jm061134b
45. Brenke, R.; Kozakov, D.; Chuang, G. Y.; Beglov, D.; Hall, D.; Landon, M. R.; Mattos, C.; Vajda, S. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques Bioinformatics 2009, 25, 621-7 10.1093/bioinformatics/btp036
46. Landon, M. R.; Lieberman, R. L.; Hoang, Q. Q.; Ju, S.; Caaveiro, J. M.; Orwig, S. D.; Kozakov, D.; Brenke, R.; Chuang, G. Y.; Beglov, D.; Vajda, S.; Petsko, G. A.; Ringe, D. Detection of ligand binding hot spots on protein surfaces via fragment-based methods: Application to DJ-1 and glucocerebrosidase J. Comput.-Aided Mol. Des. 2009, 23, 491-500 10.1007/s10822-009-9283-2
47. Kozakov, D.; Chuang, G. Y.; Beglov, D.; Vajda, S. Where does amantadine bind to the influenza virus M2 proton channel? Trends Biochem. Sci. 2010, 35, 471-5 10.1016/j.tibs.2010.03.006
48. Kozakov, D.; Hall, D. R.; Chuang, G. Y.; Cencic, R.; Brenke, R.; Grove, L. E.; Beglov, D.; Pelletier, J.; Whitty, A.; Vajda, S. Structural conservation of druggable hot spots in protein-protein interfaces Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 13528-33 10.1073/pnas.1101835108
49. Hall, D. H.; Grove, L. E.; Yueh, C.; Ngan, C. H.; Kozakov, D.; Vajda, S. Robust identification of binding hot spots using continuum electrostatics: Application to hen egg-white lysozyme J. Am. Chem. Soc. 2011, 133, 20668-71 10.1021/ja207914y
50. Hall, D. R.; Ngan, C. H.; Zerbe, B. S.; Kozakov, D.; Vajda, S. Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery J. Chem. Inf. Model. 2012, 52, 199-209 10.1021/ci200468p
51. Golden, M. S.; Cote, S. M.; Sayeg, M.; Zerbe, B. S.; Villar, E. A.; Beglov, D.; Sazinsky, S. L.; Georgiadis, R. M.; Vajda, S.; Kozakov, D.; Whitty, A. Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interface J. Am. Chem. Soc. 2013, 135, 6242-56 10.1021/ja400914z
52. Kozakov, D.; Grove, L. E.; Hall, D. R.; Bohnuud, T.; Mottarella, S. E.; Luo, L.; Xia, B.; Beglov, D.; Vajda, S. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins Nat. Protoc. 2015, 10, 733-55 10.1038/nprot.2015.043
53. Liepinsh, E.; Otting, G. Organic solvents identify specific ligand binding sites on protein surfaces Nat. Biotechnol. 1997, 15, 264-8 10.1038/nbt0397-264
54. Mattos, C.; Bellamacina, C. R.; Peisach, E.; Pereira, A.; Vitkup, D.; Petsko, G. A.; Ringe, D. Multiple solvent crystal structures: Probing binding sites, plasticity and hydration J. Mol. Biol. 2006, 357, 1471-82 10.1016/j.jmb.2006.01.039
55. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-42 10.1093/nar/28.1.235
56. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192 10.1038/nchem.217
57. Chen, Y.; Shoichet, B. K. Molecular docking and ligand specificity in fragment-based inhibitor discovery Nat. Chem. Biol. 2009, 5, 358-64 10.1038/nchembio.155
58. Warr, W. A. Fragment-based drug discovery J. Comput.-Aided Mol. Des. 2009, 23, 453-8 10.1007/s10822-009-9292-1
59. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-80 10.1021/jm8000373
60. Carr, R. A.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: Leads by design Drug Discovery Today 2005, 10, 987-92 10.1016/S1359-6446(05)03511-7
61. Villar, E. A.; Beglov, D.; Chennamadhavuni, S.; Porco, J. A.; Kozakov, D.; Vajda, S.; Whitty, A. How proteins bind macrocycles Nat. Chem. Biol. 2014, 10, 723-31 10.1038/nchembio.1584
62. Ganesan, A. The impact of natural products upon modern drug discovery Curr. Opin. Chem. Biol. 2008, 12, 306-17 10.1016/j.cbpa.2008.03.016
63. Goodman, C. M.; Choi, S.; Shandler, S.; DeGrado, W. F. Foldamers as versatile frameworks for the design and evolution of function Nat. Chem. Biol. 2007, 3, 252-262 10.1038/nchembio876
64. Zuckermann, R. N.; Kodadek, T. Peptoids as potential therapeutics Curr. Opin. Mol. Ther. 2009, 11, 299-307
65. Dietrich, U.; Durr, R.; Koch, J. Peptides as drugs: From screening to application Curr. Pharm. Biotechnol. 2013, 14, 501-12 10.2174/13892010113149990205
66. Wilson, K. P.; Yamashita, M. M.; Sintchak, M. D.; Rotstein, S. H.; Murcko, M. A.; Boger, J.; Thomson, J. A.; Fitzgibbon, M. J.; Black, J. R.; Navia, M. A. Comparative x-ray structures of the major binding-protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin Acta Crystallogr., Sect. D: Biol. Crystallogr. 1995, 51, 511-21 10.1107/S0907444994014514
67. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure of Bcl-x(L)-BAK peptide complex: Recognition between regulators of apoptosis Science 1997, 275, 983-6 10.1126/science.275.5302.983
68. Holt, D. A.; Luengo, J. I.; Yamashita, D. S.; Oh, H. J.; Konialian, A. L.; Yen, H. K.; Rozamus, L. W.; Brandt, M.; Bossard, M. J.; Levy, M. A.; Eggleston, D. S.; Liang, J.; Schultz, L. W.; Stout, T. J.; Clardy, J. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal-structures of their complexes with FKBP12 J. Am. Chem. Soc. 1993, 115, 9925-38 10.1021/ja00075a008
69. Sich, C.; Improta, S.; Cowley, D. J.; Guenet, C.; Merly, J. P.; Teufel, M.; Saudek, V. Solution structure of a neurotrophic ligand bound to FKBP12 and its effects on protein dynamics Eur. J. Biochem. 2000, 267, 5342-54 10.1046/j.1432-1327.2000.01551.x
70. Silberstein, M.; Dennis, S.; Brown, L.; Kortvelyesi, T.; Clodfelter, K.; Vajda, S. Identification of substrate binding sites in enzymes by computational solvent mapping J. Mol. Biol. 2003, 332, 1095-113 10.1016/j.jmb.2003.08.019
71. Bohnuud, T.; Kozakov, D.; Vajda, S. Evidence of conformational selection driving the formation of ligand binding sites in protein-protein interfaces PLoS Comput. Biol. 2014, 10, e1003872 10.1371/journal.pcbi.1003872
72. Wang, R.; Fang, X.; Lu, Y.; Wang, S. The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures J. Med. Chem. 2004, 47, 2977-80 10.1021/jm030580l
73. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 2007, 35, D198-201 10.1093/nar/gkl999
74. Benson, M. L.; Smith, R. D.; Khazanov, N. A.; Dimcheff, B.; Beaver, J.; Dresslar, P.; Nerothin, J.; Carlson, H. A. Binding MOAD, a high-quality protein-ligand database Nucleic Acids Res. 2007, 36, D674-8 10.1093/nar/gkm911
75. Topalis, D.; Kumamoto, H.; Velasco, M. F. A.; Dugue, L.; Haouz, A.; Alexandre, J. A. C.; Gallois-Montbrun, S.; Alzari, P. M.; Pochet, S.; Agrofoglio, L. A.; Deville-Bonne, D. Nucleotide binding to human UMP-CMP kinase using fluorescent derivatives-a screening based on affinity for the UMP-CMP binding site FEBS J. 2007, 274, 3704-14 10.1111/j.1742-4658.2007.05902.x
76. Mashhoon, N.; Pruss, C.; Carroll, M.; Johnson, P. H.; Reich, N. O. Selective inhibitors of bacterial DNA adenine methyltransferases J. Biomol. Screening 2006, 11, 497-510 10.1177/1087057106287933
77. Miao, B. C.; Skidan, I.; Yang, J. S.; Lugovskoy, A.; Reibarkh, M.; Long, K.; Brazell, T.; Durugkar, K. A.; Maki, J.; Ramana, C. V.; Schaffhausen, B.; Wagner, G.; Torchilin, V.; Yuan, J. Y.; Degterev, A. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (pip3) binding to pleckstrin homology domains Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20126-31 10.1073/pnas.1004522107
78. Lerner, C. G.; Hajduk, P. J.; Wagner, R.; Wagenaar, F. L.; Woodall, C.; Gu, Y. G.; Searle, X. B.; Florjancic, A. S.; Zhang, T.; Clark, R. F.; Cooper, C. S.; Mack, J. C.; Yu, L.; Cai, M.; Betz, S. F.; Chovan, L. E.; McCall, J. O.; Black-Schaefer, C. L.; Kakavas, S. J.; Schurdak, M. E.; Comess, K. M.; Walter, K. A.; Edalji, R.; Dorwin, S. A.; Smith, R. A.; Hebert, E. J.; Harlan, J. E.; Metzger, R. E.; Merta, P. J.; Baranowski, J. L.; Coen, M. L.; Thornewell, S. J.; Shivakumar, A. G.; Saiki, A. Y.; Soni, N.; Bui, M.; Balli, D. J.; Sanders, W. J.; Nilius, A. M.; Holzman, T. F.; Fesik, S. W.; Beutel, B. A. From bacterial genomes to novel antibacterial agents: Discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae Chem. Biol. Drug Des. 2007, 69, 395-404 10.1111/j.1747-0285.2007.00521.x
79. Piserchio, A.; Salinas, G. D.; Li, T.; Marshall, J.; Spaller, M. R.; Mierke, D. F. Targeting specific PDZ domains of PSD-95: Structural basis for enhanced affinity and enzymatic stability of a cyclic peptide Chem. Biol. 2004, 11, 469-73 10.1016/j.chembiol.2004.03.013
80. Wintjens, R.; Wieruszeski, J. M.; Drobecq, H.; Rousselot-Pailley, P.; Buee, L.; Lippens, G.; Landrieu, I. 1H NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides J. Biol. Chem. 2001, 276, 25150-6 10.1074/jbc.M010327200
81. Guo, C. X.; Hou, X. J.; Dong, L. M.; Dagostino, E.; Greasley, S.; Ferre, R.; Marakovits, J.; Johnson, M. C.; Matthews, D.; Mroczkowski, B.; Parge, H.; VanArsdale, T.; Popoff, I.; Piraino, J.; Margosiak, S.; Thomson, J.; Los, G.; Murray, B. W. Structure-based design of novel human Pin1 inhibitors (I) Bioorg. Med. Chem. Lett. 2009, 19, 5613-6 10.1016/j.bmcl.2009.08.034
82. Dong, L. M.; Marakovits, J.; Hou, X. J.; Guo, C. X.; Greasley, S.; Dagostino, E.; Ferre, R.; Johnson, M. C.; Kraynov, E.; Thomson, J.; Pathak, V.; Murray, B. W. Structure-based design of novel human Pin1 inhibitors (II) Bioorg. Med. Chem. Lett. 2010, 20, 2210-4 10.1016/j.bmcl.2010.02.033
83. Guo, C. X.; Hou, X. J.; Dong, L. M.; Marakovits, J.; Greasley, S.; Dagostino, E.; Ferre, R.; Johnson, M. C.; Humphries, P. S.; Li, H. T.; Paderes, G. D.; Piraino, J.; Kraynov, E.; Murray, B. W. Structure-based design of novel human Pin1 inhibitors (III): Optimizing affinity beyond the phosphate recognition pocket Bioorg. Med. Chem. Lett. 2014, 24, 4187-91 10.1016/j.bmcl.2014.07.044
84. Wendt, M. D.; Sun, C. H.; Kunzer, A.; Sauer, D.; Sarris, K.; Hoff, E.; Yu, L. P.; Nettesheim, D. G.; Chen, J.; Jin, S.; Comess, K. M.; Fan, Y. H.; Anderson, S. N.; Isaac, B.; Olejniczak, E. T.; Hajduk, P. J.; Rosenberg, S. H.; Elmore, S. W. Discovery of a novel small molecule binding site of human survivin Bioorg. Med. Chem. Lett. 2007, 17, 3122-9 10.1016/j.bmcl.2007.03.042
85. Huth, J. R.; Yu, L.; Collins, I.; Mack, J.; Mendoza, R.; Isaac, B.; Braddock, D. T.; Muchmore, S. W.; Comess, K. M.; Fesik, S. W.; Clore, G. M.; Levens, D.; Hajduk, P. J. NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter J. Med. Chem. 2004, 47, 4851-7 10.1021/jm0497803
86. Hajduk, P. J.; Dinges, J.; Miknis, G. F.; Merlock, M.; Middleton, T.; Kempf, D. J.; Egan, D. A.; Walter, K. A.; Robins, T. S.; Shuker, S. B.; Holzman, T. F.; Fesik, S. W. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein J. Med. Chem. 1997, 40, 3144-50 10.1021/jm9703404
87. Schaal, T. D.; Mallet, W. G.; McMinn, D. L.; Nguyen, N. V.; Sopko, M. M.; John, S.; Parekh, B. S. Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides Nucleic Acids Res. 2003, 31, 1282-91 10.1093/nar/gkg206
88. Kurg, R.; Langel, U.; Ustav, M. Inhibition of the bovine papillomavirus E2 protein activity by peptide nucleic acid Virus Res. 2000, 66, 39-50 10.1016/S0168-1702(99)00124-0
89. de Dios, A.; Prieto, L.; Martin, J. A.; Rubio, A.; Ezquerra, J.; Tebbe, M.; Lopez de Uralde, B.; Martin, J.; Sanchez, A.; LeTourneau, D. L.; McGee, J. E.; Boylan, C.; Parr, T. R., Jr.; Smith, M. C. 4-substituted D-glutamic acid analogues: The first potent inhibitors of glutamate racemase (MurI) enzyme with antibacterial activity J. Med. Chem. 2002, 45, 4559-70 10.1021/jm020901d
90. Geng, B.; Breault, G.; Comita-Prevoir, J.; Petrichko, R.; Eyermann, C.; Lundqvist, T.; Doig, P.; Gorseth, E.; Noonan, B. Exploring 9-benzyl purines as inhibitors of glutamate racemase (MurI) gram-positive bacteria Bioorg. Med. Chem. Lett. 2008, 18, 4368-4372 10.1016/j.bmcl.2008.06.068
91. Breault, G. A.; Comita-Prevoir, J.; Eyermann, C. J.; Geng, B.; Petrichko, R.; Doig, P.; Gorseth, E.; Noonan, B. Exploring 8-benzyl pteridine-6,7-diones as inhibitors of glutamate racemase (MurI) in gram-positive bacteria Bioorg. Med. Chem. Lett. 2008, 18, 6100-6103 10.1016/j.bmcl.2008.10.022
92. McRee, D. E.; Jensen, G. M.; Fitzgerald, M. M.; Siegel, H. A.; Goodin, D. B. Construction of a bisaquo heme enzyme and binding by exogenous ligands Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 12847-51 10.1073/pnas.91.26.12847
93. Appleby, C. A.; Wittenberg, B. A.; Wittenberg, J. B. Nicotinic-acid as a ligand affecting leghemoglobin structure and oxygen reactivity Proc. Natl. Acad. Sci. U. S. A. 1973, 70, 564-8 10.1073/pnas.70.2.564
94. Maldonado, S.; Lostao, A.; Irun, M. P.; Fernandez-Recio, J.; Genzor, C. G.; Gonzalez, E. B.; Rubio, J. A.; Luquita, A.; Daoudi, F.; Sancho, J. Apoflavodoxin: Structure, stability, and FMN binding Biochimie 1998, 80, 813-20 10.1016/S0300-9084(00)88876-8
95. Irie, K.; Oie, K.; Nakahara, A.; Yanai, Y.; Ohigashi, H.; Wender, P. A.; Fukuda, H.; Konishi, H.; Kikkawa, U. Molecular basis for protein kinase c isozyme-selective binding: The synthesis, folding, and phorbol ester binding of the cysteine-rich domains of all protein kinase c isozymes J. Am. Chem. Soc. 1998, 120, 9159-67 10.1021/ja981087f
96. Murray, I. A.; Cann, P. A.; Day, P. J.; Derrick, J. P.; Sutcliffe, M. J.; Shaw, W. V.; Leslie, A. G. W. Steroid recognition by chloramphenicol acetyltransferase-engineering and structural-analysis of a high-affinity fusidic acid-binding site J. Mol. Biol. 1995, 254, 993-1005 10.1006/jmbi.1995.0671
97. Vyas, M. N.; Vyas, N. K.; Quiocho, F. A. Crystallographic analysis of the epimeric and anomeric specificity of the periplasmic transport chemosensory protein-receptor for D-glucose and D-galactose Biochemistry 1994, 33, 4762-8 10.1021/bi00182a003
98. Chung, S. J.; Fromme, J. C.; Verdine, G. L. Structure of human cytidine deaminase bound to a potent inhibitor J. Med. Chem. 2005, 48, 658-60 10.1021/jm0496279
99. Masaki, T.; Tanaka, T.; Tsunasawa, S.; Sakiyama, F.; Soejima, M. Inhibition of achromobacter protease-I by lysinal derivatives Biosci., Biotechnol., Biochem. 1992, 56, 1604-7 10.1271/bbb.56.1604
100. Lunney, E. A.; Para, K. S.; Rubin, J. R.; Humblet, C.; Fergus, J. H.; Marks, J. S.; Sawyer, T. K. Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain J. Am. Chem. Soc. 1997, 119, 12471-6 10.1021/ja971794t
101. Fauman, E. B.; Rai, B. K.; Huang, E. S. Structure-based druggability assessment - identifying suitable targets for small molecule therapeutics Curr. Opin. Chem. Biol. 2011, 15, 463-8 10.1016/j.cbpa.2011.05.020
102. Schonthal, A. H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy Br. J. Cancer 2007, 97, 1465-8 10.1038/sj.bjc.6604049
103. Stangier, J.; Clemens, A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor Clin. Appl. Thromb./Hemostasis 2009, 15, 9S-16S 10.1177/1076029609343004
104. Kong, Y.; Chen, H.; Wang, Y. Q.; Meng, L.; Wei, J. F. Direct thrombin inhibitors: Patents 2002-2012 (review) Mol. Med. Rep. 2014, 9, 1506-14 10.3892/mmr.2014.2025
105. Fu, K. P.; Neu, H. C. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins Antimicrob. Agents Chemother. 1978, 13, 358-67 10.1128/AAC.13.3.358
106. van Berkel, S. S.; Nettleship, J. E.; Leung, I. K.; Brem, J.; Choi, H.; Stuart, D. I.; Claridge, T. D.; McDonough, M. A.; Owens, R. J.; Ren, J.; Schofield, C. J. Binding of (5s)-penicilloic acid to penicillin binding protein 3 ACS Chem. Biol. 2013, 8, 2112-6 10.1021/cb400200h
107. Patchett, A. A.; Harris, E.; Tristram, E. W.; Wyvratt, M. J.; Wu, M. T.; Taub, D.; Peterson, E. R.; Ikeler, T. J.; ten Broeke, J.; Payne, L. G.; Ondeyka, D. L.; Thorsett, E. D.; Greenlee, W. J.; Lohr, N. S.; Hoffsommer, R. D.; Joshua, H.; Ruyle, W. V.; Rothrock, J. W.; Aster, S. D.; Maycock, A. L.; Robinson, F. M.; Hirschmann, R.; Sweet, C. S.; Ulm, E. H.; Gross, D. M.; Vassil, T. C.; Stone, C. A. A new class of angiotensin-converting enzyme inhibitors Nature 1980, 288, 280-3 10.1038/288280a0
108. Gubareva, L. V.; Kaiser, L.; Hayden, F. G. Influenza virus neuraminidase inhibitors Lancet 2000, 355, 827-35 10.1016/S0140-6736(99)11433-8
109. Maignan, S.; Guilloteau, J. P.; Pouzieux, S.; Choi-Sledeski, Y. M.; Becker, M. R.; Klein, S. I.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. Crystal structures of human factor Xa complexed with potent inhibitors J. Med. Chem. 2000, 43, 3226-32 10.1021/jm000940u
110. Istvan, E. S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase Science 2001, 292, 1160-4 10.1126/science.1059344
111. Barrett, D. G.; Deaton, D. N.; Hassell, A. M.; McFadyen, R. B.; Miller, A. B.; Miller, L. R.; Payne, J. A.; Shewchuk, L. M.; Willard, D. H., Jr.; Wright, L. L. Acyclic cyanamide-based inhibitors of cathepsin K Bioorg. Med. Chem. Lett. 2005, 15, 3039-43 10.1016/j.bmcl.2005.04.032
112. Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.; Duong, L. T.; Falgueyret, J. P.; Kimmel, D. B.; Lamontagne, S.; Leger, S.; LeRiche, T.; Li, C. S.; Masse, F.; McKay, D. J.; Nicoll-Griffith, D. A.; Oballa, R. M.; Palmer, J. T.; Percival, M. D.; Riendeau, D.; Robichaud, J.; Rodan, G. A.; Rodan, S. B.; Seto, C.; Therien, M.; Truong, V. L.; Venuti, M. C.; Wesolowski, G.; Young, R. N.; Zamboni, R.; Black, W. C. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg. Med. Chem. Lett. 2008, 18, 923-8 10.1016/j.bmcl.2007.12.047
113. Brixen, K.; Chapurlat, R.; Cheung, A. M.; Keaveny, T. M.; Fuerst, T.; Engelke, K.; Recker, R.; Dardzinski, B.; Verbruggen, N.; Ather, S.; Rosenberg, E.; de Papp, A. E. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial J. Clin. Endocrinol. Metab. 2013, 98, 571-80 10.1210/jc.2012-2972
114. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 2008, 51, 5843-55 10.1021/jm800245z
115. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: Current status and future prospects J. Med. Chem. 2000, 43, 305-41 10.1021/jm990412m
116. Reigan, P.; Edwards, P. N.; Gbaj, A.; Cole, C.; Barry, S. T.; Page, K. M.; Ashton, S. E.; Luke, R. W. A.; Douglas, K. T.; Stratford, I. J.; Jaffar, M.; Bryce, R. A.; Freeman, S. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs J. Med. Chem. 2005, 48, 392-402 10.1021/jm049494r
117. Manikowski, A.; Verri, A.; Lossani, A.; Gebhardt, B. M.; Gambino, J.; Focher, F.; Spadari, S.; Wright, G. E. Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: Structure-activity relationships and antiherpetic activity in vivo J. Med. Chem. 2005, 48, 3919-29 10.1021/jm049059x
118. Clements, J. M.; Beckett, R. P.; Brown, A.; Catlin, G.; Lobell, M.; Palan, S.; Thomas, W.; Whittaker, M.; Wood, S.; Salama, S.; Baker, P. J.; Rodgers, H. F.; Barynin, V.; Rice, D. W.; Hunter, M. G. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor Antimicrob. Agents Chemother. 2001, 45, 563-70 10.1128/AAC.45.2.563-570.2001
119. Koropatkin, N. M.; Cleland, W. W.; Holden, H. M. Kinetic and structural analysis of alpha-d-glucose-1-phosphate cytidylyltransferase from salmonella typhi J. Biol. Chem. 2005, 280, 10774-80 10.1074/jbc.M414111200
120. Heffron, S. E.; Jurnak, F. Structure of an EF-Tu complex with a thiazolyl peptide antibiotic determined at 2.35 Å resolution: Atomic basis for GE2270A inhibition of EF-Tu Biochemistry 2000, 39, 37-45 10.1021/bi9913597
121. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-9 10.1038/nature06526
122. Whitty, A.; Kumaravel, G. Between a rock and a hard place? Nat. Chem. Biol. 2006, 2, 112-8 10.1038/nchembio0306-112
123. Fuller, J. C.; Burgoyne, N. J.; Jackson, R. M. Predicting druggable binding sites at the protein-protein interface Drug Discovery Today 2009, 14, 155-61 10.1016/j.drudis.2008.10.009
124. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J. M.; Krimm, I. Fragment-based deconstruction of Bcl-x(L) inhibitors J. Med. Chem. 2010, 53, 2577-88 10.1021/jm100009z
125. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-81 10.1038/nature03579
126. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. Abt-263: A potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 2008, 68, 3421-8 10.1158/0008-5472.CAN-07-5836
127. Tao, Z. F.; Hasvold, L.; Wang, L.; Wang, X.; Petros, A. M.; Park, C. H.; Boghaert, E. R.; Catron, N. D.; Chen, J.; Colman, P. M.; Czabotar, P. E.; Deshayes, K.; Fairbrother, W. J.; Flygare, J. A.; Hymowitz, S. G.; Jin, S.; Judge, R. A.; Koehler, M. F.; Kovar, P. J.; Lessene, G.; Mitten, M. J.; Ndubaku, C. O.; Nimmer, P.; Purkey, H. E.; Oleksijew, A.; Phillips, D. C.; Sleebs, B. E.; Smith, B. J.; Smith, M. L.; Tahir, S. K.; Watson, K. G.; Xiao, Y.; Xue, J.; Zhang, H.; Zobel, K.; Rosenberg, S. H.; Tse, C.; Leverson, J. D.; Elmore, S. W.; Souers, A. J. Discovery of a potent and selective bcl-xl inhibitor with in vivo activity ACS Med. Chem. Lett. 2014, 5, 1088-93 10.1021/ml5001867
128. Flygare, J. A.; Beresini, M.; Budha, N.; Chan, H.; Chan, I. T.; Cheeti, S.; Cohen, F.; Deshayes, K.; Doerner, K.; Eckhardt, S. G.; Elliott, L. O.; Feng, B. N.; Franklin, M. C.; Reisner, S. F.; Gazzard, L.; Halladay, J.; Hymowitz, S. G.; La, H.; LoRusso, P.; Maurer, B.; Murray, L.; Plise, E.; Quan, C.; Stephan, J. P.; Young, S. G.; Tom, J.; Tsui, V.; Um, J.; Varfolomeev, E.; Vucic, D.; Wagner, A. J.; Wallweber, H. J. A.; Wang, L.; Ware, J.; Wen, Z. Y.; Wong, H.; Wong, J. M.; Wong, M.; Wong, S.; Yu, R.; Zobel, K.; Fairbrother, W. J. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152) J. Med. Chem. 2012, 55, 4101-13 10.1021/jm300060k
129. Seigal, B. A.; Connors, W. H.; Fraley, A.; Borzilleri, R. M.; Carter, P. H.; Emanuel, S. L.; Fargnoli, J.; Kim, K.; Lei, M.; Naglich, J. G.; Pokross, M. E.; Posy, S. L.; Shen, H.; Surti, N.; Talbott, R.; Zhang, Y.; Terrett, N. K. The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity J. Med. Chem. 2015, 58, 2855-61 10.1021/jm501892g
130. Vassilev, L. T. MDM2 inhibitors for cancer therapy Trends Mol. Med. 2007, 13, 23-31 10.1016/j.molmed.2006.11.002
131. Zhao, Y.; Aguilar, A.; Bernard, D.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment J. Med. Chem. 2015, 58, 1038-52 10.1021/jm501092z
132. Sun, D.; Li, Z.; Rew, Y.; Gribble, M.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chen, X.; Chow, D.; Deignan, J.; Duquette, J.; Eksterowicz, J.; Fisher, B.; Fox, B. M.; Fu, J.; Gonzalez, A. Z.; Gonzalez-Lopez De Turiso, F.; Houze, J. B.; Huang, X.; Jiang, M.; Jin, L.; Kayser, F.; Liu, J. J.; Lo, M. C.; Long, A. M.; Lucas, B.; McGee, L. R.; McIntosh, J.; Mihalic, J.; Oliner, J. D.; Osgood, T.; Peterson, M. L.; Roveto, P.; Saiki, A. Y.; Shaffer, P.; Toteva, M.; Wang, Y.; Wang, Y. C.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Yu, M.; Zhao, X.; Zhou, J.; Zhu, J.; Olson, S. H.; Medina, J. C. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development J. Med. Chem. 2014, 57, 1454-72 10.1021/jm401753e
133. Yu, M.; Wang, Y.; Zhu, J.; Bartberger, M. D.; Canon, J.; Chen, A.; Chow, D.; Eksterowicz, J.; Fox, B.; Fu, J.; Gribble, M.; Huang, X.; Li, Z.; Liu, J. J.; Lo, M. C.; McMinn, D.; Oliner, J. D.; Osgood, T.; Rew, Y.; Saiki, A. Y.; Shaffer, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Olson, S. H.; Medina, J. C.; Sun, D. Discovery of potent and simplified piperidinone-based inhibitors of the MDM2-p53 interaction ACS Med. Chem. Lett. 2014, 5, 894-9 10.1021/ml500142b
134. Wendt, M. D.; Rockway, T. W.; Geyer, A.; McClellan, W.; Weitzberg, M.; Zhao, X.; Mantei, R.; Nienaber, V. L.; Stewart, K.; Klinghofer, V.; Giranda, V. L. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution J. Med. Chem. 2004, 47, 303-24 10.1021/jm0300072
135. D'Abramo, C. M.; Archambault, J. Small molecule inhibitors of human papillomavirus protein-protein interactions Open Virol. J. 2011, 5, 80-95 10.2174/1874357901105010080
136. Sun, Q.; Burke, J. P.; Phan, J.; Burns, M. C.; Olejniczak, E. T.; Waterson, A. G.; Lee, T.; Rossanese, O. W.; Fesik, S. W. Discovery of small molecules that bind to K-Ras and inhibit SOS-mediated activation Angew. Chem., Int. Ed. 2012, 51, 6140-3 10.1002/anie.201201358
137. Pikul, S.; Dunham, K. M.; Almstead, N. G.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Williams, L. E.; Hynd, B. A.; Hsieh, L. C.; Janusz, M. J.; Gu, F.; Mieling, G. E. Heterocycle-based MMP inhibitors with P2′ substituents Bioorg. Med. Chem. Lett. 2001, 11, 1009-13 10.1016/S0960-894X(01)00137-8
138. Kozakov, D.; Hall, D. R.; Jehle, S.; Luo, L.; Ochiana, S. O.; Jones, E. V.; Pollastri, M.; Allen, K. N.; Whitty, A.; Vajda, S. Ligand deconstruction: Why some fragment binding positions are conserved and others are not Proc. Natl. Acad. Sci. U. S. A. 2015, 112, E2585-94 10.1073/pnas.1501567112
139. Mosyak, L.; Zhang, Y.; Glasfeld, E.; Haney, S.; Stahl, M.; Seehra, J.; Somers, W. S. The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography EMBO J. 2000, 19, 3179-91 10.1093/emboj/19.13.3179
140. Jennings, L. D.; Foreman, K. W.; Rush, T. S., 3rd; Tsao, D. H.; Mosyak, L.; Li, Y.; Sukhdeo, M. N.; Ding, W.; Dushin, E. G.; Kenny, C. H.; Moghazeh, S. L.; Petersen, P. J.; Ruzin, A. V.; Tuckman, M.; Sutherland, A. G. Design and synthesis of indolo[2,3-a]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction Bioorg. Med. Chem. Lett. 2004, 14, 1427-31 10.1016/j.bmcl.2004.01.028
141. Kenny, C. H.; Ding, W. D.; Kelleher, K.; Benard, S.; Dushin, E. G.; Sutherland, A. G.; Mosyak, L.; Kriz, R.; Ellestad, G. Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction Anal. Biochem. 2003, 323, 224-33 10.1016/j.ab.2003.08.033
142. Tsao, D. H.; Sutherland, A. G.; Jennings, L. D.; Li, Y.; Rush, T. S., 3rd; Alvarez, J. C.; Ding, W.; Dushin, E. G.; Dushin, R. G.; Haney, S. A.; Kenny, C. H.; Malakian, A. K.; Nilakantan, R.; Mosyak, L. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design Bioorg. Med. Chem. 2006, 14, 7953-61 10.1016/j.bmc.2006.07.050
143. Jennings, L. D.; Foreman, K. W.; Rush, T. S.; Tsao, D. H. H.; Mosyak, L.; Kincaid, S. L.; Sukhdeo, M. N.; Sutherland, A. G.; Ding, W. D.; Kenny, C. H.; Sabus, C. L.; Liu, H. L.; Dushin, E. G.; Moghazeh, S. L.; Labthavikul, P.; Petersen, P. J.; Tuckman, M.; Haney, S. A.; Ruzin, A. V. Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction Bioorg. Med. Chem. 2004, 12, 5115-31 10.1016/j.bmc.2004.07.031
144. Rush, T. S.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-95 10.1021/jm040163o
145. Rai, G.; Vyjayanti, V. N.; Dorjsuren, D.; Simeonov, A.; Jadhav, A.; Wilson, D. M., 3rd; Maloney, D. J. Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors J. Med. Chem. 2012, 55, 3101-12 10.1021/jm201537d
146. Abbotts, R.; Madhusudan, S. Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancer Cancer Treat. Rev. 2010, 36, 425-35 10.1016/j.ctrv.2009.12.006
147. Wilson, D. M.; Simeonov, A. Small molecule inhibitors of DNA repair nuclease activities of APE1 Cell. Mol. Life Sci. 2010, 67, 3621-31 10.1007/s00018-010-0488-2
148. Patel, D.; Jain, M.; Shah, S. R.; Bahekar, R.; Jadav, P.; Joharapurkar, A.; Dhanesha, N.; Shaikh, M.; Sairam, K. V.; Kapadnis, P. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 1111-7 10.1016/j.bmcl.2011.11.122
149. Scapin, G.; Patel, S. B.; Becker, J. W.; Wang, Q. P.; Desponts, C.; Waddleton, D.; Skorey, K.; Cromlish, W.; Bayly, C.; Therien, M.; Gauthier, J. Y.; Li, C. S.; Lau, C. K.; Ramachandran, C.; Kennedy, B. P.; Asante-Appiah, E. The structural basis for the selectivity of benzotriazole inhibitors of PTP1B Biochemistry 2003, 42, 11451-9 10.1021/bi035098j
150. Barr, A. J. Protein tyrosine phosphatases as drug targets: Strategies and challenges of inhibitor development Future Med. Chem. 2010, 2, 1563-76 10.4155/fmc.10.241
151. Douty, B.; Wayland, B.; Ala, P. J.; Bower, M. J.; Pruitt, J.; Bostrom, L.; Wei, M.; Klabe, R.; Gonneville, L.; Wynn, R.; Burn, T. C.; Liu, P. C. C.; Combs, A. P.; Yue, E. W. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines Bioorg. Med. Chem. Lett. 2008, 18, 66-71 10.1016/j.bmcl.2007.11.012
152. Zhao, J.; Du, Y. H.; Horton, J. R.; Upadhyay, A. K.; Lou, B.; Bai, Y.; Zhang, X.; Du, L. P.; Li, M. Y.; Wang, B. H.; Zhang, L. X.; Barbieri, J. T.; Khuri, F. R.; Cheng, X. D.; Fu, H. A. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 16212-6 10.1073/pnas.1100012108
153. Gardino, A. K.; Smerdon, S. J.; Yaffe, M. B. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: A comparison of the x-ray crystal structures of all human 14-3-3 isoforms Semin. Cancer Biol. 2006, 16, 173-82 10.1016/j.semcancer.2006.03.007
154. De Vries-van Leeuwen, I. J.; da Costa Pereira, D.; Flach, K. D.; Piersma, S. R.; Haase, C.; Bier, D.; Yalcin, Z.; Michalides, R.; Feenstra, K. A.; Jimenez, C. R.; de Greef, T. F.; Brunsveld, L.; Ottmann, C.; Zwart, W.; de Boer, A. H. Interaction of 14-3-3 proteins with the estrogen receptor alpha f domain provides a drug target interface Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 8894-9 10.1073/pnas.1220809110
155. Thiel, P.; Roglin, L.; Meissner, N.; Hennig, S.; Kohlbacher, O.; Ottmann, C. Virtual screening and experimental validation reveal novel small-molecule inhibitors of 14-3-3 protein-protein interactions Chem. Commun. (Cambridge, U. K.) 2013, 49, 8468-70 10.1039/c3cc44612c
156. Wang, Y.; Kaiser, C. E.; Frett, B.; Li, H. Y. Targeting mutant kras for anticancer therapeutics: A review of novel small molecule modulators J. Med. Chem. 2013, 56, 5219-30 10.1021/jm3017706
157. Feig, L. A.; Cooper, G. M. Inhibition of NIH-3T3 cell-proliferation by a mutant Ras protein with preferential affinity for GDP Mol. Cell. Biol. 1988, 8, 3235-43
158. Maurer, T.; Garrenton, L. S.; Oh, A.; Pitts, K.; Anderson, D. J.; Skelton, N. J.; Fauber, B. P.; Pan, B.; Malek, S.; Stokoe, D.; Ludlam, M. J.; Bowman, K. K.; Wu, J.; Giannetti, A. M.; Starovasnik, M. A.; Mellman, I.; Jackson, P. K.; Rudolph, J.; Wang, W.; Fang, G. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 5299-304 10.1073/pnas.1116510109
159. Wang, W. R.; Fang, G. W.; Rudolph, J. Ras inhibition via direct Ras binding-is there a path forward? Bioorg. Med. Chem. Lett. 2012, 22, 5766-76 10.1016/j.bmcl.2012.07.082
160. Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Nature 2013, 503, 548-51 10.1038/nature12796
161. Christ, F.; Debyser, Z. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy Virology 2013, 435, 102-9 10.1016/j.virol.2012.09.033
162. Malet, I.; Calvez, V.; Marcelin, A. G. The future of integrase inhibitors of HIV-1 Curr. Opin. Virol. 2012, 2, 580-7 10.1016/j.coviro.2012.08.005
163. Demeulemeester, J.; Chaltin, P.; Marchand, A.; De Maeyer, M.; Debyser, Z.; Christ, F. LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: A patent review (2006-2014) Expert Opin. Ther. Pat. 2014, 24, 609-32 10.1517/13543776.2014.898753